Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Bexarotene in Women at High Risk for Breast Cancer
NCT03323658Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2018
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of bexarotene in breast cancer (3 arms), sponsored by National Cancer Institute. Primary endpoint: Incidence of Adverse Events (Dose Limiting Toxicities). Started Jun 2018; status: completed.
02
Drugs
bexarotene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03323658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03323658.